secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001654954-23-001545
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica sees Q4 rev $6.0-6.2M (+46-51% YoY); FY rev up ~360%
-------------------------------------------------------------

- Q4 2022 revenue expected $6.0-$6.2M, +46-51% vs Q4 2021, driven by PulseVet and Assisi.
- Full-year 2022 revenue expected $18.6-$18.9M, +354-361% over 2021.
- Gross margin for FY 2022 expected ~72%.
- Cash, cash equivalents and available-for-sale securities ~$156M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495423001545/0001654954-23-001545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495423001545/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-001545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer